Hatem A Azim

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
  2. doi Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy
    Hatem A Azim
    BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Breast 24:290-3. 2015
  3. doi RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, boulevard de Waterloo, 121, Brussels, BE 1000, Belgium
    Breast Cancer Res 17:538. 2015
  4. pmc Managing pregnant women with cancer: personal considerations and a review of the literature
    Ha Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Ecancermedicalscience 5:204. 2011
  5. pmc Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 31:73-9. 2013
  6. doi Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies
    Hatem A Azim
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium
    Cancer Treat Rev 38:834-42. 2012
  7. doi Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet and l Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Breast Cancer Res Treat 133:387-91. 2012
  8. ncbi Managing cancer during pregnancy: what evidence do we have?
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Pol Arch Med Wewn 121:29-34. 2011
  9. doi Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
  10. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011

Detail Information

Publications22

  1. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  2. doi Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy
    Hatem A Azim
    BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Breast 24:290-3. 2015
    ..Tumour infiltrating lymphocytes (TILs) is one of the most exciting breast cancer biomarkers, yet no data is available on its prevalence in tumours diagnosed during pregnancy...
  3. doi RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, boulevard de Waterloo, 121, Brussels, BE 1000, Belgium
    Breast Cancer Res 17:538. 2015
    ..No clinical data is available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients...
  4. pmc Managing pregnant women with cancer: personal considerations and a review of the literature
    Ha Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Ecancermedicalscience 5:204. 2011
    ..In this review we touch on the available evidence on managing cancer patients diagnosed during the course of pregnancy in an attempt to provide some guidance for clinicians dealing with such cases...
  5. pmc Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 31:73-9. 2013
    ..We questioned the impact of pregnancy on disease-free survival (DFS) in women with history of breast cancer (BC) according to estrogen receptor (ER) status...
  6. doi Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies
    Hatem A Azim
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium
    Cancer Treat Rev 38:834-42. 2012
    ..Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis...
  7. doi Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet and l Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Breast Cancer Res Treat 133:387-91. 2012
    ..We are currently initiating a collaboration to collect similar data from the other large adjuvant trastuzumab trials to confirm these findings...
  8. ncbi Managing cancer during pregnancy: what evidence do we have?
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Pol Arch Med Wewn 121:29-34. 2011
    ..In this review, we will consider the available evidence for managing pregnant women with cancer to provide some guidance for physicians dealing with these patients...
  9. doi Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
    ....
  10. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  11. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
    ..SPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast cancer (BC)...
  12. doi Biology of breast cancer during pregnancy using genomic profiling
    Hatem A Azim
    Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Department of Forest Ecology
    Endocr Relat Cancer 21:545-54. 2014
    ..No genes were associated with DFS in a multivariate model, which could be due to low statistical power. Diagnosis during pregnancy impacts the breast cancer transcriptome including potential cancer targets...
  13. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
    ..We critically analyse the available evidence and provide some insights on how to manage these toxicities in the clinical setting...
  14. doi Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 47:74-83. 2011
    ..Hence, we conducted a meta-analysis to understand the effect of pregnancy on overall survival of women with a history of breast cancer...
  15. doi Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012
    ..Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age...
  16. doi Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
    Evandro de Azambuja
    Institut Jules Bordet and Breast European Adjuvant Study Team, Brussels, Belgium Electronic address
    Lancet Oncol 15:1137-46. 2014
    ..Here, we report data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response...
  17. doi Rituximab in Hodgkin lymphoma: is the target always a hit?
    Kamal S Saini
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 37:385-90. 2011
    ..A systematic review of the literature is also presented...
  18. doi Motherhood after breast cancer: searching for la dolce vita
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 11:287-98. 2011
    ..In addition, we will discuss the different fertility-preservation techniques available for these patients...
  19. doi An update on PARP inhibitors--moving to the adjuvant setting
    Amir Sonnenblick
    BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Boulevard de Waterloo 125, B 1000 Brussels, Belgium
    Nat Rev Clin Oncol 12:27-41. 2015
    ..The specific considerations and challenges that might be encountered when implementing these compounds in the adjuvant treatment of breast cancer in the clinic are also highlighted. ..
  20. doi New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors
    Amir Sonnenblick
    BrEAST Data Center, Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 20:6242-6. 2014
    ..Clin Cancer Res; 20(24); 6242-6. ©2014 AACR. ..
  21. doi Clinical development of new formulations of cytotoxics in solid tumors
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 24:325-31. 2012
    ..To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy...
  22. doi Simultaneous targeting of estrogen receptor and HER2 in breast cancer
    Hatem A Azim
    Jules Bordet Institute, Department of Medical Oncology, Boulevard Waterloo, 121, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 10:1255-63. 2010
    ..We analyze clinical evidence regarding the combined use of AIs and anti-HER2-targeted agents. We also touch on possible mechanisms of resistance and ways to improve research in this field...